Ruskovska, Tatjana (2002) Influence of lovastatin on the oxidative stress and on the IgG autoantibodies against MDA-modified LDL particles in patients with dyslipidemia. PhD thesis, Ss. Cyril and Methodius University.
Preview |
Text
Докторска дисертација.pdf Download (1MB) | Preview |
Abstract
Although there is increasing evidence that high serum concentrations of autoantibodies against oxidised LDL (anti-oxLDL) are connected with increased risk for coronary heart disease (CHD), there are some opposite findings. That is why the aim of this study was to find out if concentrations of anti-oxLDL were higher in patients (men and women) with advanced CHD that were selected for myocardial revascularization than in healthy controls and to investigate the influence of lovastatin and antioxidant therapy on anti-oxLDL concentrations.
In the study were included 40 patients with CHD (20 men and 20 women) and 40, sex and age matched, healthy normolipidemic controls. We have measured: total cholesterol (CHOL), triacylglycerols (TRIG), HDL-cholesterol (HDL), LDL-cholesterol (LDL), apolipoprotein A1 (apoA1), apolipoprotein B (apoB), lipoprotein (a) [Lp(a)], serum hydroperoxides and anti-oxLDL.
Patients had significantly higher concentrations of CHOL, TRIG, LDL and apoB and lower concentrations of HDL and apoA1 than controls (p<0.01 for all parameters), as well as significantly higher concentrations of Lp(a), (p<0.05). Among patients, women had significantly higher HDL and apoA1 than men (p<0.01 and p<0.25 respectively). Women with CHD had significantly higher serum hydroperoxides than controls (p<0.01) and men with CHD (p<0.01), while anti-oxLDL were significantly higher in men with CHD than in controls (262+/-160 : 165+/-77 mU/ml; p<0.05). Among men with CHD there was positive correlation between anti-oxLDL and apoB/apoA1 ratio (p<0.05).
Lovastatin treatment induced significant lowering of anti-oxLDL (212+/-102 : 188+/-94 mU/ml; p<0.01) in 30 patients with primary dyslipidemia. Antioxidant therapy (500 mg vitamin C and 100 mg vitamin E) did not change concentrations of anti-oxLDL in 20 patients on hemodialysis (233+/-131 : 241+/-119 mU/ml; p>0.05.
From these results we conclude that anti-oxLDL can be considered as a risk factor for CHD, especially in men. Sex difference for serum hydroperoxides and anti-oxLDL in patients with CHD could in part explain the sex difference of morbidity and mortality from CHD. Lovastatin, but not antioxidant treatment, lowers serum concentrations of anti-oxLDL.
| Item Type: | Thesis (PhD) |
|---|---|
| Subjects: | Medical and Health Sciences > Basic medicine Medical and Health Sciences > Clinical medicine |
| Divisions: | Faculty of Medical Science |
| Depositing User: | Tatjana Ruskovska |
| Date Deposited: | 02 Dec 2012 10:06 |
| Last Modified: | 02 Dec 2012 10:06 |
| URI: | https://eprints.ugd.edu.mk/id/eprint/2718 |
Actions (login required)
 |
View Item |